Market Overview

The Risk/Reward Potential For Exelixis Has Balanced As Catalysts Loom

Share:

Deutsche Bank analyst Andrew Peters downgraded shares of Exelixis, Inc (NASDAQ: EXEL) on Thursday, while raising his price target from $26 to $29.

The company had been Deutsche Bank’s top pick since initiating coverage on the biotech sector last year.

The downgrade wasn't a result of downsides ahead though, Peters sees Exelixis “as an undisputed success story in biotech.” Instead, the company is simply lack new catalysts.

The data from CELESTIAL's Phase 3 trial will be available later this year and the combination of cabozantinib and I/O agents could prove to be differentiating, but the Peters’ price target already accounts for significant upside from both.

The next de-risking events for the programs are expected to be over a year away.

Exelixis is “one that we believe will continue to garner strategic interest,” said Peters, but investors shouldn’t expect any near-term gains.

The company reported EPS and sales for the second quarter above consensus estimates, but share price gains were short lived, with the stock having dropped 5.7 percent from its intraday high — from $27.38 to $25.85.

Keep up with earnings season and analyst coverage in real-time with Benzinga Pro.

Related Links:

Teva's Quarter: Earnings Miss, Guidance Cut, Dividend Devastated

Illumina Beats In Q2, But Investment Thesis Remains Unclear

Latest Ratings for EXEL

DateFirmActionFromTo
Aug 2019MaintainsHold
Mar 2019UpgradesUnderweightEqual-Weight
Feb 2019Initiates Coverage OnMarket Perform

View More Analyst Ratings for EXEL
View the Latest Analyst Ratings

Posted-In: Andrew Peters Deutsche BankAnalyst Color Downgrades Price Target Analyst Ratings

 

Related Articles (EXEL)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
NCMIBenchmarkMaintains12.0
FWONAFBN SecuritiesDowngrades
BXCitiDowngrades52.0
TRVBank of AmericaDowngrades
PSTGCross ResearchUpgrades
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

DISH Network Execs Play Coy On Amazon Deal

Allstate Investors, Are You In Good Hands? Deutsche Downgrades Stock Seeing Resistance Ahead